Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.

Hamilton SH, Revicki DA, Edgell ET, Genduso LA, Tollefson G.

Pharmacoeconomics. 1999 May;15(5):469-80.

PMID:
10537964
2.

[Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].

Le Pen C, Lilliu H, Allicar MP, Olivier V, Gregor KJ.

Encephale. 1999 Jul-Aug;25(4):281-6. French.

PMID:
10546082
3.

Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.

Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A.

Pharmacoeconomics. 2000 Dec;18(6):567-79.

PMID:
11227395
4.

Olanzapine: an updated review of its use in the management of schizophrenia.

Bhana N, Foster RH, Olney R, Plosker GL.

Drugs. 2001;61(1):111-61. Review.

PMID:
11217867
5.

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.

Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Campbell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V; Department of Veterans Affairs Cooperative Study Group on the Cost-Effectiveness of Olanzapine.

JAMA. 2003 Nov 26;290(20):2693-702.

PMID:
14645311
6.

Olanzapine. A pharmacoeconomic review of its use in schizophrenia.

Foster RH, Goa KL.

Pharmacoeconomics. 1999 Jun;15(6):611-40. Review.

PMID:
10538333
7.
8.

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia.

Glazer WM, Johnstone BM.

J Clin Psychiatry. 1997;58 Suppl 10:50-4. Review.

9.
10.

Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample.

Hamilton SH, Edgell ET, Revicki DA, Breier A.

Int Clin Psychopharmacol. 2000 Sep;15(5):245-55.

PMID:
10993126
11.
12.

A cost-effectiveness clinical decision analysis model for schizophrenia.

Palmer CS, Revicki DA, Genduso LA, Hamilton SH, Brown RE.

Am J Manag Care. 1998 Mar;4(3):345-55.

13.

Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol.

Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM; HGDH Study Group.

Am J Psychiatry. 2003 Aug;160(8):1396-404.

PMID:
12900300
14.

A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy.

Wright P, Meehan K, Birkett M, Lindborg SR, Taylor CC, Morris P, Breier A.

Clin Ther. 2003 May;25(5):1420-8.

PMID:
12867218
16.

Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.

Gureje O, Miles W, Keks N, Grainger D, Lambert T, McGrath J, Tran P, Catts S, Fraser A, Hustig H, Andersen S, Crawford AM.

Schizophr Res. 2003 Jun 1;61(2-3):303-14.

PMID:
12729882
17.

Olanzapine versus haloperidol treatment in first-episode psychosis.

Sanger TM, Lieberman JA, Tohen M, Grundy S, Beasley C Jr, Tollefson GD.

Am J Psychiatry. 1999 Jan;156(1):79-87.

PMID:
9892301
18.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
19.

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.

Hamilton SH, Revicki DA, Genduso LA, Beasley CM Jr.

Neuropsychopharmacology. 1998 Jan;18(1):41-9.

20.

[Cost effectiveness analysis of olanzapine versus haloperidol in the treatment of schizophrenia++ in Spain].

Sacristán JA, Gómez JC, Salvador-Carulla L.

Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1997 Jul-Aug;25(4):225-34. Spanish.

PMID:
9412161

Supplemental Content

Support Center